Cancer Biomarkers Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 59.1 billion
Estimated Base Value
2035 Forecast
US$ 162.8 billion
Projected Market Value
CAGR 2026–2035
10.7%
Compound Annual Growth
Largest Segment
Protein Biomarkers
Fastest Growing Segment
Epigenetic Biomarkers
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
45.0% market share
Key Players
Exact Sciences
Emerging Players
Lucence, C2i Genomics
Market Definition & Overview
The Cancer Biomarkers Market encompasses the development, manufacturing, and commercialization of biological molecules and associated assays used to detect the presence of cancer, assess disease progression, predict treatment response, and monitor recurrence. This market is pivotal for advancing precision medicine within the pharmaceutical industry, enabling highly targeted therapies and personalized treatment regimens. It includes a range of diagnostic tests, kits, and services leveraging genomic, proteomic, metabolomic, and other molecular markers found in various bodily fluids or tissues. Key applications span early detection, risk stratification, companion diagnostics for specific pharmaceutical drugs, and post-treatment surveillance, driving innovation in oncology and improving patient outcomes through tailored medical interventions.
Scope
- Global market coverage across all major regions
- Analysis of diagnostic, prognostic, and predictive biomarker applications in oncology
- Market sizing and forecast from 2023 to 2030
Inclusions
- Biomarker assays and kits for cancer diagnosis, prognosis, and monitoring
- Companion diagnostics (CDx) for guiding targeted cancer therapies
- Technologies for genomic, proteomic, and epigenomic biomarker analysis
- Services for biomarker discovery, validation, and commercialization support
- Research tools and reagents specifically for cancer biomarker studies
- In vitro diagnostic (IVD) devices leveraging cancer-specific molecular markers
Exclusions
- General medical diagnostic devices not utilizing specific cancer biomarkers
- Therapeutic pharmaceutical drugs themselves, independent of biomarker guidance
- Biomarkers unrelated to cancer conditions or their treatment
- Basic research consumables and equipment not specific to biomarker analysis
- Surgical instruments or general laboratory automation platforms
- Direct patient care services not involving biomarker testing
Market Size Forecast
Executive Summary
• The Cancer Biomarkers market is valued at $59.1 Bn in 2025 and is forecast to reach $162.8 Bn by 2035, reflecting a robust CAGR of 10.7% as demand accelerates across every major segment and region over the ten-year outlook.
• Protein Biomarkers leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 42.1%, while Emerging Areas is expanding the fastest at a 9.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 45.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic collaborations between diagnostic developers and pharmaceutical giants are intensifying, signaling a robust trend toward vertically integrated precision oncology solutions and influencing the competitive landscape across key global markets.
• The accelerated integration of next-generation sequencing and liquid biopsy technologies, alongside evolving regulatory frameworks, is fundamentally reshaping biomarker discovery and validation pathways, particularly in advanced cancer diagnostics.
• Expanding clinical utility beyond initial diagnosis to include therapy selection and recurrence monitoring represents a significant growth catalyst, pushing biomarker integration deeper into personalized cancer treatment paradigms worldwide.
• Differentiated market penetration across specific cancer types and varying regional reimbursement policies necessitate tailored strategic approaches for sustained growth, with emerging economies poised for substantial, albeit nascent, adoption.
• Significant venture capital investment continues to fuel innovation in AI-driven biomarker platforms and data analytics, crucial for scaling personalized medicine and optimizing diagnostic assay development pipelines globally.
• The paradigm shift towards multi-omic profiling and companion diagnostics is driving demand for comprehensive biomarker panels, compelling stakeholders to prioritize interoperability and data standardization for future market leadership.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The cancer biomarkers market was valued at $59.1 billion in the base year, indicating its substantial foundational size within the precision medicine industry.
Robust Growth Outlook
The market is projected to achieve a valuation of $162.8 billion by the forecast year, demonstrating significant future expansion.
Double-Digit Expansion
A remarkable compound annual growth rate (CAGR) of 10.7% is anticipated for the cancer biomarkers market, signifying rapid growth potential.
Market Projection
From its $59.1 billion base year value, the cancer biomarkers market is set for a substantial increase to $162.8 billion by the forecast year, driven by diagnostic advancements.
Precision Medicine Driver
Cancer biomarkers are a critical component driving the expansion of precision medicine in oncology, enabling personalized therapeutic and diagnostic approaches.
Liquid Biopsy Trend
The increasing integration and adoption of liquid biopsies represent a notable trend, offering less invasive and more dynamic insights into cancer progression and treatment response.
Market Dynamics
Market Trends
- Liquid biopsy adoption is rising for non-invasive cancer detection.
- AI and machine learning are increasingly used for biomarker discovery.
- Multi-omics data integration offers comprehensive patient profiling.
- Focus on companion diagnostics for targeted cancer therapies is growing.
Growth Drivers
- Rising global cancer incidence fuels demand for biomarkers.
- Growing need for personalized oncology treatments drives market.
- Technological advancements enhance biomarker discovery and analysis.
- Increased R&D spending in cancer diagnostics propels growth.
Restraints
- High development and validation costs limit market growth.
- Stringent regulatory pathways delay biomarker approval and adoption.
- Lack of standardization impacts test accuracy and clinical utility.
- Reimbursement challenges hinder broad market accessibility.
Opportunities
- Early cancer detection and risk assessment offer vast potential.
- Developing biomarkers for immunotherapy response prediction is key.
- Untapped emerging markets present significant growth avenues.
- Strategic partnerships can integrate biomarkers into drug development.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Protein BiomarkersGenetic & Genomic BiomarkersEpigenetic BiomarkersCirculating Tumor Cell BiomarkersCirculating Tumor DNA BiomarkersMetabolomic BiomarkersGlycosylation Biomarkers |
| By Application | DiagnosisPrognosisTheragnostics & Treatment SelectionDisease MonitoringDrug Discovery & Development |
| By Technology | Next Generation SequencingPolymerase Chain ReactionImmunohistochemistryMass SpectrometryFlow CytometryMicroarraysEnzyme-Linked Immunosorbent Assay |
| By Cancer Type | Lung CancerBreast CancerColorectal CancerProstate CancerMelanomaLeukemia & LymphomaOvarian CancerOthers |
| By End-User | Hospitals & ClinicsDiagnostic LaboratoriesAcademic & Research InstitutesPharmaceutical & Biotechnology CompaniesContract Research Organizations |
| By Source | Tissue BiopsiesBlood SamplesOther Body Fluid SamplesCell LinesAnimal Models |
Regional Analysis
- North America leads the cancer biomarkers market due to its robust R&D infrastructure, high adoption of advanced diagnostics, and significant investment in precision medicine. A large patient pool and early access to innovative therapies further solidify its dominant position.
- The Asia-Pacific region is the fastest-growing market, driven by increasing healthcare expenditure, rising cancer incidence, and improving diagnostic facilities. Growing awareness of personalized medicine and supportive government initiatives further fuel its expansion.
- Europe is seeing a noteworthy trend with increasing adoption of liquid biopsies for cancer detection and monitoring. This non-invasive method offers significant advantages for early diagnosis and personalized treatment tracking, gaining traction across the region as a less intrusive patient management approach.
Asia Pacific
8.1% CAGR
$24.9 Bn
42.1% share
- This region holds the largest market share, driven by increasing cancer incidence, improving healthcare infrastructure, and growing government initiatives for precision medicine across key economies like China and India.
North America
7.8% CAGR
$16.5 Bn
28% share
- A significant market segment characterized by advanced R&D capabilities, high adoption rates of personalized medicine, and a strong presence of leading pharmaceutical and biotech companies.
Europe
7.5% CAGR
$11.2 Bn
19% share
- This region maintains a substantial market share, supported by robust healthcare spending, established research institutions, and a rising focus on early cancer diagnosis and targeted therapies.
Latin America
8.5% CAGR
$3.3 Bn
5.5% share
- An emerging market experiencing rapid growth due to increasing healthcare expenditure, improving access to advanced diagnostics, and a growing awareness of precision oncology benefits.
Middle East & Africa
8.2% CAGR
$2.2 Bn
3.8% share
- This developing market shows promising growth potential, fueled by rising investments in healthcare infrastructure, increasing prevalence of cancer, and efforts to modernize diagnostic capabilities in select countries.
Emerging Areas
9.0% CAGR
$945.6 Mn
1.6% share
- Representing smaller, nascent geographies, this segment exhibits the highest growth rate from a low base, driven by improving economic conditions, expanding healthcare access, and nascent adoption of cancer biomarker technologies.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $26.6 Bn | 8.5% | The U.S. leads the global cancer biomarkers market due to extensive R&D investments, a strong presence of pharmaceutical and biotech companies, and high adoption rates of advanced diagnostic technologies for precision oncology. Its robust regulatory framework and high healthcare spending further fuel market growth. |
| 2 | Brazil | $1.8 Bn | 11.0% | As the largest economy in Latin America, Brazil offers a substantial patient pool and increasing healthcare expenditure, driving demand for precision oncology and advanced cancer biomarker testing. Government initiatives to improve cancer care also contribute to its market growth. |
| 3 | Germany | $3.2 Bn | 8.8% | Germany boasts a leading pharmaceutical sector, significant R&D spending, and an advanced healthcare system, making it a key player in the European cancer biomarkers market. Early adoption of precision medicine and strong genomic research initiatives drive its growth. |
| 4 | China | $7.1 Bn | 13.0% | China represents a rapidly expanding market due to its immense patient population, rising healthcare expenditure, and significant government backing for biotech innovation and precision medicine initiatives. Domestic companies are rapidly developing and adopting advanced biomarker technologies. |
| 5 | Saudi Arabia | $1.2 Bn | 12.0% | Saudi Arabia is heavily investing in upgrading its healthcare infrastructure and adopting advanced medical technologies, including precision oncology and cancer biomarkers. A high prevalence of certain cancers further drives the demand for innovative diagnostic solutions. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Exact Sciences | 5.7% | Expand market share in early cancer detection and precision oncology through highly accurate diagnostic tests and a comprehensive portfolio. | It is widely recognized for its non-invasive colorectal cancer screening test, Cologuard, which has achieved significant market penetration. | Significantly expanded its precision oncology offerings through the acquisition of Genomic Health and its Oncotype DX franchise. | CologuardOncotype DXOncotype MAP+1 |
| 2 | Guardant Health | 5.4% | Dominate the liquid biopsy market for advanced cancer treatment selection, recurrence monitoring, and early detection. | A leader in liquid biopsy technology, providing comprehensive genomic profiling for advanced cancers through a simple blood draw. | Launched Guardant Reveal for adjuvant therapy selection and recurrence monitoring in early-stage colorectal cancer, expanding its clinical utility. | Guardant360Guardant RevealGuardant Health AMEA+1 |
| 3 | Natera | 5.1% | Leverage its personalized molecular residual disease (MRD) testing platform, Signatera, to become a standard of care for cancer recurrence monitoring. | Specializes in cell-free DNA testing, with a strong focus on oncology through its highly sensitive Signatera MRD platform. | Secured additional positive coverage decisions and presented strong clinical data supporting the use of Signatera in multiple cancer types. | SignateraPanoramaProspera+1 |
| 4 | Caris Life Sciences | 4.9% | Provide comprehensive molecular profiling and artificial intelligence-driven insights to guide precision cancer therapy for patients and drug development. | Offers one of the most comprehensive molecular profiling platforms, integrating DNA, RNA, and protein analysis to deliver personalized treatment guidance. | Expanded its Caris Molecular Intelligence platform with advanced AI-driven drug response prediction and new biomarker discovery initiatives. | Caris Molecular IntelligenceCaris MI ExomeCaris MI Transcriptome+1 |
| 5 | Tempus | 4.6% | Build the world's largest library of clinical and molecular data to power precision medicine and accelerate drug discovery. | Combines comprehensive genomic sequencing with clinical data and AI to provide personalized insights for cancer care and research. | Partnered with multiple pharmaceutical companies to leverage its AI platform for biomarker discovery and clinical trial matching, extending its reach. | Tempus xTTempus xETempus xR+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Exact Sciences, Guardant Health, Natera, Caris Life Sciences, Tempus, Qiagen, Myriad Genetics, Veracyte, NeoGenomics, Adaptive Biotechnologies, Freenome, Personalis, Biodesix, MDxHealth, Burning Rock Biotech, Epigenomics AG, Oncocyte, Angle plc, VolitionRx, DiaCarta
The global Cancer Biomarkers market features a competitive landscape led by Exact Sciences, Guardant Health, Natera, Caris Life Sciences, Tempus, and Qiagen, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Exact Sciences
Guardant Health
Natera
Caris Life Sciences
Tempus
Qiagen
Myriad Genetics
Veracyte
NeoGenomics
Adaptive Biotechnologies
Freenome
Personalis
Biodesix
MDxHealth
Burning Rock Biotech
Epigenomics AG
Oncocyte
Angle plc
VolitionRx
DiaCarta
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Guardant Health Launches Enhanced Liquid Biopsy for Early Cancer Detection
Guardant Health announced the commercial launch of its new multi-cancer early detection liquid biopsy test, offering improved sensitivity and specificity across various solid tumors. This expands access to non-invasive screening methods for a broader patient population.
Roche Acquires AI-Driven Biomarker Discovery Firm 'BioPredict Solutions'
Roche Diagnostics completed the acquisition of BioPredict Solutions, a startup specializing in AI-driven biomarker discovery and validation for immuno-oncology. This strategic move aims to bolster Roche's precision medicine pipeline and accelerate the identification of novel therapeutic targets.
Eli Lilly Forms Strategic Alliance with Illumina for Companion Diagnostics
Eli Lilly and Illumina entered a multi-year partnership to develop companion diagnostic tests for Lilly's pipeline of oncology therapeutics. The collaboration will leverage Illumina's next-generation sequencing platforms to identify predictive biomarkers, enhancing treatment personalization.
GRAIL Secures $300M in Funding to Advance Multi-Cancer Early Detection Research
GRAIL, a leader in multi-cancer early detection, announced a significant new funding round of $300 million to accelerate clinical trials and expand its research and development capabilities for next-generation biomarker platforms. This investment underscores confidence in the future of liquid biopsy technologies.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $59.1 Bn |
| Market Size (Forecast) | $162.8 Bn |
| CAGR | 10.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 37 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included